<DOC>
	<DOCNO>NCT01589809</DOCNO>
	<brief_summary>The purpose interventional study determine whether Nicotinamide effective upregulating Frataxin ( FXN ) gene patient Friedreich 's ataxia ( FRDA ) gene abnormally 'switched ' . The purpose non-interventional study investigate use novel , highly-sensitive technology capture clinical deficit measure subtle change activity daily live correlate functional change level expression Frataxin protein epigenetic structure Frataxin gene 9-12 month period without nicotinamide . Healthy volunteer include comparators part study .</brief_summary>
	<brief_title>Effect Nicotinamide Friedreich 's Ataxia</brief_title>
	<detailed_description>Friedreich 's ataxia ( FRDA ) cause GAA repeat expansion Frataxin gene cause repression resembles archetypal epigenetic phenomenon Position Effect Variegation hence modulate chromatin modifier The investigator confirm similar form silencing occur cell FRDA patient . Based finding histone deacetylase ( HDAC ) inhibitors overcome silence identify . The investigator extend result show classical Class III HDAC inhibitor , nicotinamide , relieve silence cell patient . Nicotinamide vitamin register drug previously administer human significant ill effect . In interventional study , investigator perform pharmacodynamic study nicotinamide human FRDA investigate whether investigator upregulate Frataxin , determine optimum dose regimen . Nicotinamide administer orally follow standard drug escalation regimen blood sample take measure Frataxin level chromatin structure Frataxin gene . The end-point study achieve significant upregulation Frataxin patient provide potential therapy currently untreatable condition . In non-interventional study , investigate use novel , highly-sensitive technology capture clinical deficit measure subtle change activity daily live correlate functional change level expression Frataxin protein epigenetic structure Frataxin gene 9-12 month period without nicotinamide . Healthy volunteer comparators include part study . HVs undergo assessment participant Friedreich ataxia .</detailed_description>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Inclusion Criteria interventional study 1 . Participants must molecular genetic diagnosis FRDA , consist GAArepeat expansion allele FXN gene . 2 . Participants must age 18 year live UK register GP . 3 . Participants must provide informed consent . If write consent possible due physical incapacity , write consent behalf participant seek participant 's relative carer . 4 . A female participant eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Childbearing potential agrees use one follow contraception method : True abstinence : When line prefer usual lifestyle participant . [ Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ] . Contraceptive Methods Failure Rate &lt; 1 % : Oral contraceptive , either combined progestogen alone ; Injectable progestogen ; Implants levonorgestrel ; Estrogenic vaginal ring ; Percutaneous contraceptive patch ; Intrauterine device ( IUD ) intrauterine system ( IUS ) meet &lt; 1 % failure rate state product label ; Male partner ( ) sterilisation ( vasectomy documentation azoospermia ) prior female participant entry study ; Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus vaginal spermicidal agent ( foam/gel/film/cream/suppository ) . Exclusion Criteria interventional study 1 . Participants significant clinical dysphagia . 2 . Participants take Sodium Valproate know histone deacetylase inhibitor . 3 . Participants take part another interventional clinical trial do within 30 day screen . 4 . Participants know positive human immunodeficiency virus ( HIV ) . 5 . Participants additional medical condition illness , opinion CI would interfere study compliance and/or impair participant ability participate complete study . Concurrent diseases condition may interfere study participation safety include liver disease , bleed disorder , arrhythmia , organ transplant , organ failure , current neoplasm , poorly control diabetes mellitus , poorly control hypertension , clinically significant haematological biochemical abnormality . 6 . Patients history substance abuse ( e.g . alcohol drug abuse ) within previous 6 month enrolment . 7 . Participants history severe allergy . 8 . Female participant lactate pregnant ( positive prerandomisation serum pregnancy test ) plan become pregnant study . 9 . Hypersensitivity Nicobion ( nicotinamide ) excipients preparation 10 . Liver function test outside normal range : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , bilirubin opinion CI would put participant safety risk . Inclusion Criteria noninterventional study 1 . Up 20 participant must molecular genetic diagnosis FRDA , consist GAArepeat expansion allele FXN gene . Up 20 participant must HV . 2 . Participants age 18 year , live UK register GP . 3 . Participants must provide informed consent . If write consent possible due physical incapacity , write consent behalf participant seek participant 's relative carer . 4 . Women childbearing potential must negative urine pregnancy test . Exclusion Criteria noninterventional study 1 . Contraindications MRI include , limited : intracranial aneurism clip ( except Sugita ) , history metal lathe work possibility intraorbital metal fragment , pacemaker nonMR compatible heart valve nonMR compatible implant , history claustrophobia participant feel unable lie still back period 6090mins fMRI scanner .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Congenital , familial genetic disorder</keyword>
	<keyword>Nervous System Diseases</keyword>
</DOC>